Moderna, Inc. (NASDAQ:MRNA) | WebDisclosure

Basculer en Français

10831	Companies
235078	Keywords
163941	Articles
125842	Press releases

Home
Companies
Moderna, Inc.

PRESS RELEASE

published on 09/16/2025 at 12:00, 10 months 27 days ago

Moderna Announces Updated COVID-19 Vaccine Against LP.8.1 Variant Generates Strong Immune Response in Humans
Moderna reports 8-fold increase in neutralizing antibodies with Spikevax 2025-2026 formula, reinforcing FDA approval. Clinical trial data supports efficacy against COVID-19 LP.8.1 variant

FDA Approval COVID-19 Vaccine Moderna Spikevax Neutralizing Antibodies
BRIEF

published on 09/02/2025 at 13:05, 11 months 11 days ago

Moderna présentera ses données thérapeutiques à base d'ARNm à l'ICIEM 2025

Moderne Acidémie Propionique ICIEM Thérapeutique Par ARNm Acidémie Méthylmalonique
BRIEF

published on 09/02/2025 at 13:05, 11 months 11 days ago

Moderna to Present mRNA Therapeutics Data at 2025 ICIEM

MRNA Therapeutics Moderna Propionic Acidemia ICIEM Methylmalonic Acidemia
PRESS RELEASE

published on 09/02/2025 at 13:00, 11 months 11 days ago

Moderna Announces Data to be Presented at the 2025 International Congress of Inborn Errors of Metabolism
Moderna, Inc. to present abstracts on mRNA therapeutics at the 2025 ICIEM including PA, MMA, and GSD1a programs in Kyoto, Japan. Company's first time presenting data for MMA and GSD1a

Moderna Inc. MRNA Therapeutics ICIEM Abstracts Kyoto Japan
BRIEF

published on 08/27/2025 at 19:29, 11 months 16 days ago

Moderna's Updated COVID-19 Vaccines Approved by U.S. FDA

FDA Approval COVID-19 Vaccine Moderna SARS-CoV-2 Variant Spikevax And MNEXSPIKE
BRIEF

published on 08/27/2025 at 19:29, 11 months 16 days ago

Les vaccins Moderna contre la COVID-19 mis à jour approuvés par la FDA américaine

Approbation De La FDA Moderne Vaccin Contre Le Covid-19 Variante Du SRAS-CoV-2 Spikevax Et MNEXSPIKE
PRESS RELEASE

published on 08/27/2025 at 19:24, 11 months 16 days ago

Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccines Targeting LP.8.1 Variant of SARS-CoV-2
Moderna announces FDA approval for updated Spikevax® and mNEXSPIKE® COVID-19 vaccines targeting LP.8.1 variant to prevent severe outcomes. Vaccines available soon

FDA Approval Moderna COVID-19 Vaccines Spikevax MNEXSPIKE
BRIEF

published on 08/22/2025 at 15:30, 11 months 21 days ago

Moderna Receives Health Canada Approval for Updated COVID-19 Vaccine

COVID-19 Vaccine Moderna Health Canada Approval Canadian Manufacturing Biomanufacturing Leadership
BRIEF

published on 08/22/2025 at 15:30, 11 months 21 days ago

Moderna reçoit l'approbation de Santé Canada pour son vaccin contre la COVID-19 mis à jour

Moderne Vaccin Contre Le Covid-19 Fabrication Canadienne Approbation De Santé Canada Leadership En Bioproduction
PRESS RELEASE

published on 08/22/2025 at 15:25, 11 months 21 days ago

Moderna Receives Health Canada Approval for Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant LP.8.1
Moderna's Spikevax COVID-19 vaccine for SARS-CoV-2 LP.8.1 variant authorized in Canada, with all 2025 doses produced domestically. Leadership in biomanufacturing highlighted

COVID-19 Vaccine Canada Moderna Spikevax Biomanufacturing

Accesswire

Published on 08/13/2026 at 14:31, 44 minutes ago

Wi2Wi Announces Strategic Equipment Investments to Expand Production Capacity
Published on 08/13/2026 at 14:15, 1 hour ago

Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference August 19th
Published on 08/13/2026 at 14:00, 1 hour 15 minutes ago

AEONIAN Expands Koocanusa Copper Project to Approximately 412 Km(2); Fieldwork Underway Across Four New Target Areas
Published on 08/13/2026 at 14:00, 1 hour 15 minutes ago

Adcore Reports Q2 2026 Results: Gross Margin Expands to 51% as Revenue Grows 10% to CAD$7.2 million and North America Rebounds 27% to CAD$1.5 million
Published on 08/13/2026 at 14:00, 1 hour 15 minutes ago

GameSquare Appoints Tom Wild as Vice President of Creative Strategy for EMEA

View all ACCESSWIRE

EQS Group

Published on 08/13/2026 at 14:30, 45 minutes ago

Delticom improved earnings in the first half of 2026
Published on 08/13/2026 at 14:29, 46 minutes ago

Amundi Physical Metals plc: UK Final Terms
Published on 08/13/2026 at 14:22, 53 minutes ago

Amundi Physical Metals plc: Final Terms
Published on 08/13/2026 at 14:20, 55 minutes ago

Axtria to Build Industry's Largest Pharma-Specific AI Engineering Team, Scaling to 1,000 by December 2026
Published on 08/13/2026 at 13:45, 1 hour 30 minutes ago

REINET INVESTMENTS S.C.A. ANNOUNCES SHARE BUYBACK PROGRAMME

Les Echos

Published on 08/11/2026 at 17:45, 1 day 21 hours ago

DAMARTEX / Droits de vote bruts et réels au 31 juillet 2026
Published on 08/11/2026 at 17:40, 1 day 21 hours ago

Infotel : Déclaration des transactions sur actions propres réalisées du 3 au 7 août 2026 dans le cadre du programme de rachat d’actions
Published on 08/10/2026 at 18:00, 2 days 21 hours ago

AXA: Information relating to the number of voting rights and shares making up the share capital on 31/07/2026
Published on 08/10/2026 at 18:00, 2 days 21 hours ago

AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 31/07/2026
Published on 08/10/2026 at 17:45, 2 days 21 hours ago

Weekly share buyback

View all LES ECHOS COMFI WIRE